← Back to patent-cliff list
INX-315
Tier C — Watch / tradeINX-315
Inccyclix Bio Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK2
Indications (approved)：Ovarian cancer, Breast cancer, Solid tumour, Metastatic cancer, Metastatic breast cancer
Regional status
US
Phase II
2023-03-28
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of INX-315?
Approved indications include: Ovarian cancer, Breast cancer, Solid tumour, Metastatic cancer, Metastatic breast cancer.
When does the INX-315 patent expire?
No public expiry year is available for INX-315 yet; this page updates once verified.
How do I get a quote for INX-315 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03